Home Contact Sitemap

eRAM

encyclopedia of Rare Disease Annotation for Precision Medicine




Disease barrett esophagus
Comorbidity C0279628|esophageal adenocarcinoma
Sentences 37
PubMedID- 24221456 Acid-suppressive medications and risk of oesophageal adenocarcinoma in patients with barrett's oesophagus: a systematic review and meta-analysis.
PubMedID- 26233550 Serum 25-hydroxyvitamin d levels and the risk of dysplasia and esophageal adenocarcinoma in patients with barrett's esophagus.
PubMedID- 26311716 Surveillance endoscopy is associated with improved outcomes of oesophageal adenocarcinoma detected in patients with barrett's oesophagus.
PubMedID- 25843080 Acid-suppressive medications and risk of esophageal adenocarcinoma in patients with barrett's esophagus(gut 2014;63:1229-1237).
PubMedID- 22796132 Background& aims: proton pump inhibitors and nonsteroidal anti-inflammatory drugs might prevent esophageal adenocarcinoma in patients with barrett's esophagus (be), but there are limited data from clinical trials to support this concept.
PubMedID- 23243384 For upper gi tract pathology i-scan assisted in diagnosis or therapy of barrett's esophagus with dysplasia, esophageal adenocarcinoma, hsv esophagitis, gastric malt lymphoma, gastric antral intestinal metaplasia with dysplasia, duodenal follicular lymphoma, and a flat duodenal adenoma.
PubMedID- 22443641 Previously, the risk of progression to esophageal adenocarcinoma in patients with barrett's esophagus was thought to be approximately 1%.
PubMedID- 21698030 The majority of lower esophageal adenocarcinomas appear in patients with barrett's esophagus (be), a premalignant condition in which the normal squamous epithelium is replaced by metaplastic columnar epithelium.
PubMedID- 24681073 Preference of endoscopic ablation over medical prevention of esophageal adenocarcinoma by patients with barrett's esophagus.
PubMedID- 21345220 Lgr5 expression and cancer stem cell hypothesis: clue to define the true origin of esophageal adenocarcinomas with and without barrett's esophagus.
PubMedID- 20397052 Oral bisphosphonate prescriptions and the risk of esophageal adenocarcinoma in patients with barrett's esophagus.
PubMedID- 22353776 Observational data have also indicated that statins may have protective effects against the development of cancer, for example, modifying the risk of oesophageal adenocarcinoma in patients with existing barrett's oesophagus [20].
PubMedID- 23617672 It is often difficult to accurately delineate the borders and extent of early-stage esophageal adenocarcinoma in patients with barrett's esophagus using conventional white light endoscopy.
PubMedID- 24651385 Cyclooxygenase inhibitors use is associated with reduced risk of esophageal adenocarcinoma in patients with barrett's esophagus: a meta-analysis.
PubMedID- 25071359 Lifetime risk of esophageal adenocarcinoma in patients with barrett's esophagus.
PubMedID- 22302717 There is a critical need to identify molecular markers that can reliably aid in stratifying esophageal adenocarcinoma (eac) risk in patients with barrett's esophagus.
PubMedID- 21375764 In contrast with the esophageal adenocarcinoma arising from barrett's esophagus in western countries, the major phenotype in the asia-pacific region is esophageal squamous cell carcinoma (escc) [2,3].
PubMedID- 19850156 Risk of esophageal adenocarcinoma and mortality in patients with barrett's esophagus: a systematic review and meta-analysis.
PubMedID- 22241250 Use of statin medications and risk of esophageal adenocarcinoma in persons with barrett's esophagus.
PubMedID- 22626608 Background & aims: radiofrequency ablation (rfa) reduces the risk of esophageal adenocarcinoma (eac) in patients with barrett's esophagus (be) with high-grade dysplasia (hgd), but its effects in patients without dysplasia are debatable.
PubMedID- 26202380 Overexpression of cd55 from barrett's esophagus is associated with esophageal adenocarcinoma risk.
PubMedID- 21115135 The incidence of esophageal adenocarcinoma among patients with nondysplastic barrett's esophagus has been overestimated.
PubMedID- 21593708 Incidence of esophageal adenocarcinoma with barrett esophagus (be) imposes a decision about therapy management.
PubMedID- 21309910 Dysplasia and esophageal adenocarcinoma may arise in patients with barrett's esophagus after fundoplication esophageal ph monitoring showing no acid in esophagus.
PubMedID- 23338150 Therefore, telomerase inhibitors may exhibit high potency in the treatment of esophageal adenocarcinoma arising from barrett's esophagus.
PubMedID- 20188100 However, the possible effect these medications may have on the risk of esophageal adenocarcinoma (eac) in patients with existing barrett's esophagus (be) is unclear.
PubMedID- 26208896 Background & aims: statins have been reported to protect against esophageal adenocarcinoma (eac) in patients with barrett's esophagus (be).
PubMedID- 23714382 Background & aims: recent population-based studies have shown a low risk of esophageal adenocarcinoma (eac) in patients with nondysplastic barrett's esophagus (ndbe).
PubMedID- 21820152 The progression of intestinal metaplasia to esophageal adenocarcinoma in patients with barrett's esophagus is partly driven by chromosomal alterations that activate oncogenes and inactivate tumor suppressor genes.
PubMedID- 20550712 However, to date this hypothesis remains untested.the 'exercise and the prevention of oesophageal cancer study' will determine whether 24 weeks of exercise training will lead to alterations in risk factors or biomarkers for oesophageal adenocarcinoma in males with barrett's oesophagus.
PubMedID- 25633286 Nsaids, statins, low-dose aspirin and ppis, and the risk of oesophageal adenocarcinoma among patients with barrett's oesophagus: a population-based case-control study.
PubMedID- 24570883 Advanced esophageal adenocarcinomas arising from barrett esophagus (be) are tumors with an increasing incidence and poor prognosis.
PubMedID- 25621687 The incidence of esophageal adenocarcinoma arising from barrett esophagus (be) has been rapidly increasing in many western countries over the past few decades.1–3 it also leads to increasing the rate of hospitalization for esophageal adenocarcinoma and causes a serious problem.4 endoscopic surveillance of be, the currently accepted standard, aims to reduce morbidity and mortality by early detection and endoscopic therapy of dysplasia or cancer.5–8 current guidelines from gastroenterology societies recommend endoscopic surveillance of be using white light endoscopy (wle) with targeted biopsies of any endoscopically visible lesions and 4 random quadrant biopsies from every 2 cm of the be segment (seattle protocol).7,9 however, it has been pointed out that this protocol has several limitations, such as time required, low compliance, and increased risk of sampling error.10 therefore, establishment of a more effective surveillance program for detecting dysplastic lesions or those with high malignant potential in be patients is highly desirable.
PubMedID- 24867156 Recent findings: rfa is well tolerated and efficacious in most but not all barrett's esophagus patients with dysplasia and esophageal adenocarcinoma (eac).
PubMedID- 20946664 There were n = 41 esophageal adenocarcinomas (eac) with associated barrett's esophagus (be), n = 19 eac without be and n = 10 esophageal squamous-cell carcinomas of the esophagus (which were intended to serve as positive control for mmp-1 expression), and n = 18 barrett's biopsies without intraepithelial neoplasia or invasive carcinoma which were derived from patients with gastroesophageal reflux disease (gerd).
PubMedID- 24795040 Background: proton pump inhibitors (ppis) may reduce the risk of esophageal adenocarcinoma (eac) in patients with barrett's esophagus.
PubMedID- 26068095 We explored next-generation sequencing to detect mutations with the analytical sensitivity required to predict concurrent high-grade dysplasia (hgd) and esophageal adenocarcinoma (eac) in patients with barrett's esophagus by testing nonneoplastic bim.

Page: 1